1. Home
  2. TOP vs GANX Comparison

TOP vs GANX Comparison

Compare TOP & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Financial Group Limited

TOP

TOP Financial Group Limited

N/A

Current Price

$1.15

Market Cap

43.0M

Sector

Finance

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$4.07

Market Cap

117.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOP
GANX
Founded
2015
2017
Country
Singapore
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.0M
117.7M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
TOP
GANX
Price
$1.15
$4.07
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
46.8K
1.1M
Earning Date
01-26-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,329,256.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$1.41
52 Week High
$3.33
$4.34

Technical Indicators

Market Signals
Indicator
TOP
GANX
Relative Strength Index (RSI) 54.02 75.70
Support Level $1.10 $3.94
Resistance Level $1.24 $4.34
Average True Range (ATR) 0.05 0.37
MACD 0.02 0.07
Stochastic Oscillator 59.09 88.10

Price Performance

Historical Comparison
TOP
GANX

About TOP TOP Financial Group Limited

TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: